Intervention
Lapatinib Ditosylate
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownWhole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerNCT01622868 · 2012-12-06
COMPLETEDEntinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyNCT01434303 · 2012-01-10
COMPLETEDLapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerNCT01281163 · 2011-01-01
TERMINATEDLapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituNCT00555152 · 2009-08-19
COMPLETEDPaclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryNCT00770809 · 2009-02-24
COMPLETEDCapecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerNCT00684983 · 2008-07-30
COMPLETEDFulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveNCT00390455 · 2006-09-15
COMPLETEDLapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TamoxifenNCT00118157 · 2005-05-01
COMPLETEDCommon conditions
Recurrent Breast Carcinoma6Stage IV Breast Cancer AJCC v6 and v74Estrogen Receptor Positive3HER2/Neu Positive3Progesterone Receptor Positive3Stage IIIB Breast Cancer AJCC v73Stage IIIC Breast Cancer AJCC v73HER2 Positive Breast Carcinoma2Invasive Breast Carcinoma2Male Breast Carcinoma2Stage IV Breast Cancer2Ductal Breast Carcinoma In Situ1Estrogen Receptor Negative1HER2-Positive Breast Carcinoma1HER2/Neu Negative1Metastatic Malignant Neoplasm in the Brain1Progesterone Receptor Negative1Stage IIA Breast Cancer AJCC v6 and v71Stage IIB Breast Cancer AJCC v6 and v71Stage IIIA Breast Cancer AJCC v71Stage IIIB Breast Cancer1Stage IIIC Breast Cancer1
Leading sponsors
Trial status mix
COMPLETED7
TERMINATED1
Phase mix
PHASE23
PHASE12
PHASE32
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.